Myelodysplastic Syndrome, Unclassifiable, With 1 Percent Blasts

MedGen UID:: 1718320
•Concept ID:: C5239038
•: Neoplastic Process

Definition

Myelodysplastic syndrome, unclassifiable characterized by refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1 percent blasts in the peripheral blood. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVMyelodysplastic Syndrome, Unclassifiable, With 1 Percent Blasts

Disorder by Site
- Hematopoietic and Lymphoid System Disorder
  - Hematologic disorder
    - Bone marrow disorder
      - Myelodysplastic syndrome
        Myelodysplastic Syndrome, Unclassifiable
        Myelodysplastic Syndrome, Unclassifiable, With 1 Percent Blasts

Recent clinical studies

Etiology

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M
Haematologica 2019 Mar;104(3):497-504. Epub 2018 Oct 4 doi: 10.3324/haematol.2018.203158. PMID: 30287621 Free PMC Article

See all (1)

Diagnosis

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country.

Bauduer F, Ducout L, Dastugue N, Capdupuy C, Renoux M
Leuk Res 1998 Mar;22(3):205-8. doi: 10.1016/s0145-2126(97)00159-8. PMID: 9619911

See all (2)

Therapy

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.

Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, Holowiecki J, Giebel S, Markiewicz M, Uharek L, Blau IW, Kienast J, Stelljes M, Larsson K, Zander AR, Gramatzki M, Repp R, Einsele H, Stuhler G, Baumgart J, Mylius HA, Pichlmeier U, Freund M, Casper J
Haematologica 2011 Sep;96(9):1344-50. Epub 2011 Jun 9 doi: 10.3324/haematol.2011.043810. PMID: 21659356 Free PMC Article

See all (2)